U.S. District Judge Dan Polster, who oversees roughly 2,000 opioid
lawsuits by states, counties and cities, said the plaintiffs can try
to prove that drugmakers' deceptive marketing of the painkillers
caused a harmful, massive increase in supply that pharmacies and
distributors did not do enough to stop.
"A factfinder could reasonably infer that these failures were a
substantial factor in producing the alleged harm suffered by
plaintiffs," the Cleveland-based judge wrote.
The ruling was among seven decisions and orders totaling 80 pages
from Polster ahead of a scheduled Oct. 21 trial by two Ohio counties
against Purdue Pharma, the OxyContin maker accused of fueling the
epidemic, and several other defendants.
Polster also refused to dismiss civil conspiracy claims against
drugmakers, pharmacies and distributors, and said federal law did
not preempt much of the plaintiffs' case.
Other defendants included the drugmakers Endo International Plc and
Johnson & Johnson; pharmacy operators CVS Health Corp, Rite Aid
Corp, Walgreens Boots Alliance Inc and Walmart Inc; and distributors
AmerisourceBergen Corp, Cardinal Health Inc and McKesson Corp.
Polster also refused to dismiss a variety of claims against generic
drugmakers Allergan Plc, Mallinckrodt Plc and Teva Pharmaceutical
Industries Ltd.
Opioid addiction claimed roughly 400,000 lives in the United States
from 1999 to 2017, according to the U.S. Centers for Disease Control
and Prevention.
[to top of second column] |
Critics of the industry said opioid makers hid the addiction and
abuse risks of prolonged use from consumers.
Rite Aid's lawyers declined to comment. Lawyers for other major
defendants did not immediately respond to requests for comment.
Paul Hanly, a lawyer for the plaintiffs, said his clients were
pleased that Polster "almost uniformly" agreed with their positions
on the dismissal requests and whether to admit various testimony.
J&J has said it will appeal an Oklahoma judge's Aug. 26 order that
it pay $572.1 million to that state for the company's role in the
opioid epidemic.
Purdue and its owners, the Sackler family, have been in talks on a
possible $10 billion to $12 billion nationwide settlement of opioid
claims, two people familiar with the matter said last week.
That accord could include a bankruptcy filing for the Stamford,
Connecticut-based company. Purdue and the Sacklers have denied the
allegations.
The case is In re National Prescription Opiate Litigation, U.S.
District Court, Northern District of Ohio, No. 17-md-02804.
(Reporting by Jonathan Stempel in New York; Editing by Bill Berkrot)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|